Welcome to our dedicated page for Dariohealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for DarioHealth Corp are anything but routine. A single 10-K can weave together FDA pathways, digital therapeutics algorithms, and multi-year clinical data鈥攄etails essential to gauging how its chronic-condition platform turns R&D into recurring revenue. If you鈥檝e ever opened a filing looking for patent amortization or payer adoption metrics, you know the frustration. Stock Titan solves that pain.
Our AI breaks down DarioHealth Corp annual report 10-K simplified, highlights segment revenue from employer contracts, and flags capitalized software costs in minutes. The same engine delivers bullet-proof context for each DarioHealth Corp quarterly earnings report 10-Q filing and pushes alerts for every DarioHealth Corp 8-K material events explained. Need to track DarioHealth Corp insider trading Form 4 transactions? We stream DarioHealth Corp Form 4 insider transactions real-time, mapping each executive move to option grant dates and clinical milestones. Questions like 鈥淗ow is share-based compensation trending?鈥� or 鈥淒id management sell stock before a material announcement?鈥� are answered instantly.
Whether you鈥檙e understanding DarioHealth Corp SEC documents with AI for diligence or performing a DarioHealth Corp earnings report filing analysis, the platform connects forms to real-world drivers:
- DarioHealth Corp executive stock transactions Form 4 reveal insider confidence as new condition modules launch.
- DarioHealth Corp proxy statement executive compensation links pay structures to clinical outcome targets.
- 10-Qs trace membership growth across diabetes, hypertension, and behavioral health programs.
Skip the 300-page PDFs. Stock Titan delivers concise, expert narratives, real-time updates, and the clarity investors need to act.
DarioHealth Corp. reported total revenues of $5.369 million for the quarter ended June 30, 2025, split between Services $3.661M and Consumer hardware $1.708M. Gross profit was $2.964M for the quarter and $6.846M for the six months, while operating expenses were $12.164M for the quarter, producing an operating loss of $9.200M. The company recorded a net loss of $12.990M for the quarter and $22.217M for the six months; basic and diluted loss per share was $0.18 for the quarter and $0.33 for six months.
On the balance sheet, cash and cash equivalents were $21.954M (down from $27.764M at year-end), total assets were $108.325M, and accumulated deficit totaled $422.971M. The company refinanced with a $32.5M Callodine credit agreement on April 30, 2025, but did not meet one covenant as of June 30, 2025; Callodine waived the default conditional on a successful equity cure by November 15, 2025. Management discloses that these conditions raise substantial doubt about the Company鈥檚 ability to continue as a going concern for twelve months from issuance.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
